Henry Meds Reviews: Clinical Efficacy, Genetic Screening & Provider Selection

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Henry Meds is a telehealth platform that connects patients with licensed providers to prescribe GLP-1 medications like semaglutide and tirzepatide. The platform has grown significantly, serving patients seeking weight management and metabolic support through remote consultations and pharmacy partnerships.

Full head-to-head: PlexusDx vs Henry Meds →

Choosing among telehealth GLP-1 providers requires understanding clinical assessment standards, eligibility screening, and whether genetic context enhances decision-making. PlexusDx emphasizes precision wellness by combining compounded GLP-1 options with optional genetic testing to support more informed provider conversations about individual differences in peptide-related pathways.

What Henry Meds Offers and How It Works

Henry Meds operates as a direct-to-consumer telehealth service. Patients complete an online health questionnaire, speak with a licensed provider via video, and receive a prescription if deemed appropriate. Medications are then dispensed through licensed partner compounding pharmacies.

The platform emphasizes convenience and speed. Consultations typically occur within 24–48 hours, and prescriptions are shipped directly to patients. Henry Meds is a cash-pay subscription — provider evaluation, medication, shipping, and ongoing care are included in one price, with no membership fee and $0 charged until a prescription is written — making access relatively straightforward for eligible candidates.

Clinical Assessment Standards: Henry Meds Versus Precision-Oriented Alternatives

Henry Meds providers conduct standard medical history reviews, measure BMI, and screen for contraindications such as personal or family history of thyroid cancer or pancreatitis. However, the depth of metabolic biomarker assessment or genetic context varies by provider.

Platforms taking a precision-wellness approach, such as PlexusDx, layer in optional genetic testing to reveal individual predispositions in peptide-related pathways (GIPR, FTO, MC4R variants). This additional context may help providers tailor initial dose, formulation, or monitoring strategies more specifically to each patient.

Assessment Factor	Henry Meds Standard Approach	Precision-Focused Alternative (e.g., PlexusDx)
Medical history and vitals	Questionnaire, provider review, BMI	Questionnaire, provider review, BMI
Contraindication screening	Thyroid cancer, pancreatitis history, renal function	Thyroid cancer, pancreatitis history, renal function
Metabolic biomarker depth	Variable; depends on provider	Often includes fasting glucose, lipids, HbA1c context
Genetic pathway testing	Not offered as standard	Optional Precision Peptide Genetic Test ($298)
Dose/formulation personalization	Based on clinical judgment	May integrate genetic predisposition data to guide approach

Henry Meds' Pharmacy Model and Medication Options

Henry Meds partners with licensed compounding pharmacies and retail networks to dispense medications. Most patients receive compounded semaglutide (injectable or sublingual) or tirzepatide — which Henry offers as an oral dissolving tablet only, as of July 2026 — though the specific formulation and potency may vary slightly between pharmacy partners based on state regulations and inventory.

As of July 2026, Henry lists injectable compounded semaglutide at $297/month month-to-month (6-month prepaid $1,482, about $247/month; 12-month prepaid $2,364 — the advertised “$197/month” rate, paid in full), oral sublingual semaglutide at $249/month (with a $179/month tier), oral tirzepatide dissolving tablets as a 3-month supply at $1,047 ($891 paid in full; no month-to-month rate is published), liraglutide at $179/month, and phentermine at $149/month. The subscription is cash-pay and all-inclusive — provider evaluation, shipping, and ongoing care are included, with no membership fee. When comparing plans, note whether a quoted rate is month-to-month or a prepaid-in-full advertised rate.

Clinical Evidence and GLP-1 Efficacy in Telehealth Settings

GLP-1 medications have robust clinical evidence supporting weight loss and metabolic improvement. Landmark trials show semaglutide reduces body weight by 10–15% and tirzepatide by 15–22% over 68 weeks when combined with lifestyle measures. These results hold in telehealth and in-person settings.

Henry Meds patients experience similar outcomes when they adhere to treatment protocols and maintain follow-up consultations. However, telehealth relies on patient self-reporting and home monitoring, which may introduce variability in adherence compared to clinic-based programs with in-person supervision.

Genetic Screening and Personalization Considerations

Henry Meds does not routinely offer genetic testing as part of its assessment. While clinical outcomes data do not require genetic screening for GLP-1 success, individual response patterns vary substantially. Some patients respond robustly to standard dosing; others experience side effects or plateau at lower doses.

PlexusDx's Precision Peptide Genetic Test examines variants in GIPR and FTO, and MC4R genes that may predispose individuals to differences in appetite signaling, metabolic rate, and treatment tolerability. This context can support provider conversations about dose titration strategies, formulation choice, or monitoring intensity—though genetic predisposition does not predict exact medication response.

Safety Profile and Eligibility Screening

GLP-1 medications carry established side effects including nausea, vomiting, constipation, and risk of pancreatitis in susceptible individuals. Henry Meds screens for these risks through standard questionnaires and provider review. Patients with personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) are typically ineligible.

Ongoing safety depends on adherence to dose escalation protocols, regular provider follow-up, and honest reporting of side effects. Henry Meds' telehealth model requires patients to self-monitor and communicate symptoms clearly. Patients with complex medical histories or high comorbidity burden may benefit from additional specialist consultation alongside telehealth management.

Provider Guidance: How to Choose Between Telehealth GLP-1 Platforms

When evaluating Henry Meds against other telehealth providers, consider three key factors: provider credentials (licensed MD, DO, or NP), depth of initial assessment (biomarkers, contraindication screening, discussion of side effect expectations), and continuity of care (regular follow-ups, medication adjustments, open communication channels).

Platforms integrating optional genetic testing, such as PlexusDx, add a fourth layer: the ability to align initial strategies with individual peptide pathway predispositions. This does not replace clinical judgment but may enhance conversations about why certain patients tolerate or respond differently to standard protocols.

How PlexusDx Supports a More Personalized Approach

PlexusDx uses licensed 503A compounding pharmacies exclusively, ensuring strict quality standards and ingredient transparency—a distinction from some high-volume telehealth platforms. Compounded medications allow flexibility in dosing and formulation while maintaining regulatory oversight through state pharmacy boards.

The optional Precision Peptide Genetic Test ($298) reveals individual predispositions in GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 variants. These genetic patterns may help providers contextualize why an individual patient exhibits particular appetite signaling patterns, metabolic rate tendencies, or side effect profiles—though genetic results should always be interpreted with a qualified healthcare provider and do not guarantee exact medication response.

For patients considering Henry Meds or seeking an alternative with additional personalization options, PlexusDx offers a conversation-focused approach: your provider reviews your genetic and clinical context together to craft a more tailored initial strategy and monitoring plan. This model supports informed decision-making without over-promising precision.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is Henry Meds a legitimate, regulated telehealth platform?

Yes. Henry Meds operates with licensed providers and partners with state-regulated pharmacies. The platform is compliant with telehealth regulations, though you should verify that your state permits remote GLP-1 prescribing. Always confirm your provider's credentials before starting treatment.

What are the main differences between Henry Meds and other telehealth GLP-1 providers?

Henry Meds emphasizes speed and accessibility, with consultations typically within 24–48 hours. Competitors vary in assessment depth, use of genetic screening, medication sourcing, and follow-up intensity. Some platforms, like PlexusDx, integrate optional genetic testing to inform personalized dose and formulation strategies.

Does Henry Meds offer genetic testing or biomarker assessment?

Henry Meds does not include genetic testing in its standard protocol. PlexusDx offers an optional Precision Peptide Genetic Test that examines peptide-related gene variants and may help providers tailor initial treatment approaches to individual pathway predispositions.

How much does treatment through Henry Meds cost?

As of July 2026, Henry Meds lists injectable compounded semaglutide at $297/month month-to-month (the advertised “$197/month” is its 12-month prepaid-in-full rate), oral sublingual semaglutide at $249/month, oral tirzepatide dissolving tablets as a 3-month supply at $1,047 ($891 paid in full), liraglutide at $179/month, and phentermine at $149/month. PlexusDx protocols run $129/month for the Microdose GLP-1 Protocol, $189/month for Semaglutide Injection, $289/month for Tirzepatide Injection, Semaglutide Oral, and GLP-Squared, and $349/month for Tirzepatide Oral.

Can genetic testing improve my GLP-1 treatment outcomes?

Genetic testing may help provide context for individual differences in appetite signaling and metabolic rate.

What should I ask a telehealth GLP-1 provider before starting treatment?

Ask about provider credentials, how they screen for contraindications, their approach to dose titration, frequency of follow-ups, side effect management, and whether they integrate any personalization tools (metabolic labs, genetic context, or biomarker tracking) into their protocol to support your specific situation.

Related Reading

• Henry Meds Glp 1
• Henry Meds Tirzepatide
• Henry Meds Cost
• Henry Review Plexusdx

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.